BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72:785-801. [PMID: 32059982 DOI: 10.1016/j.jhep.2020.01.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Reja M, Patel R, Pioppo L, Tawadros A, Bhurwal A, Marino D, Rustgi V. Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2021;55:433-8. [PMID: 32740097 DOI: 10.1097/MCG.0000000000001389] [Reference Citation Analysis]
2 Tanabe H, Saito H, Kudo A, Machii N, Hirai H, Maimaituxun G, Tanaka K, Masuzaki H, Watanabe T, Asahi K, Kazama J, Shimabukuro M. Factors Associated with Risk of Diabetic Complications in Novel Cluster-Based Diabetes Subgroups: A Japanese Retrospective Cohort Study. J Clin Med 2020;9:E2083. [PMID: 32630741 DOI: 10.3390/jcm9072083] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
3 Li S, Wu Y, Jiang H, Zhou F, Ben A, Wang R, Hua C. Chicory polysaccharides alleviate high-fat diet-induced non-alcoholic fatty liver disease via alteration of lipid metabolism- and inflammation-related gene expression. Food Science and Human Wellness 2022;11:954-64. [DOI: 10.1016/j.fshw.2022.03.025] [Reference Citation Analysis]
4 Fernández-Mincone T, Contreras-Briceño F, Espinosa-Ramírez M, García-Valdés P, López-Fuenzalida A, Riquelme A, Arab JP, Cabrera D, Arrese M, Barrera F. Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications. Expert Rev Gastroenterol Hepatol 2020;14:1141-57. [PMID: 32811209 DOI: 10.1080/17474124.2020.1810563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhang M, Lin S, Wang MF, Huang JF, Liu SY, Wu SM, Zhang HY, Wu ZM, Liu WY, Zhang DC, Hao CM, Zhu YY, Zheng MH, Wang XZ. Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west? BMC Gastroenterol 2020;20:139. [PMID: 32375660 DOI: 10.1186/s12876-020-01278-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Guo W, Lu J, Qin P, Li X, Zhu W, Wu J, Xu N, Zhang Q. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults. Lipids Health Dis 2020;19:218. [PMID: 33028338 DOI: 10.1186/s12944-020-01393-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Zou H, Xu Y, Meng X, Li D, Chen X, Du T, Yang Y, Chen Y, Shao S, Yuan G, Zhou X, Hu S, He W, Ma D, Xie J, Zhang B, Zhang J, Li W, Liu Z, Yu X. Circulating ANGPTL8 levels and risk of kidney function decline: Results from the 4C Study. Cardiovasc Diabetol 2021;20:127. [PMID: 34167540 DOI: 10.1186/s12933-021-01317-3] [Reference Citation Analysis]
8 Mertens J, Van Gaal LF, Francque SM, De Block C. NAFLD in type 1 diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab 2021;12:20420188211055557. [PMID: 34840719 DOI: 10.1177/20420188211055557] [Reference Citation Analysis]
9 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zou Z, Fan J. Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease. Journal of Hepatology 2020;73:214-6. [DOI: 10.1016/j.jhep.2020.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Di Sessa A, Guarino S, Melone R, De Simone RF, Marzuillo P, Miraglia del Giudice E. Relationship between nonalcoholic fatty liver disease and chronic kidney disease could start in childhood. World J Gastroenterol 2021; 27(34): 5793-5795 [PMID: 34629802 DOI: 10.3748/wjg.v27.i34.5793] [Reference Citation Analysis]
12 Männistö VT, Salomaa V, Färkkilä M, Jula A, Männistö S, Erlund I, Sundvall J, Lundqvist A, Perola M, Åberg F. Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. Liver Int 2021. [PMID: 34219352 DOI: 10.1111/liv.15004] [Reference Citation Analysis]
13 Jung CY, Ryu GW, Kim HW, Ahn SH, Kim SU, Kim BS. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia 2021. [PMID: 34932136 DOI: 10.1007/s00125-021-05627-9] [Reference Citation Analysis]
14 Targher G. What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. Metabolites. 2020;10. [PMID: 33049948 DOI: 10.3390/metabo10100397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
16 Moein H, Arteaga EJ, Sarkar S. Using Telehealth for Diagnosis and Management of Non‐Alcoholic Fatty Liver Disease. Clinical Liver Disease 2022;19:171-5. [DOI: 10.1002/cld.1191] [Reference Citation Analysis]
17 Al-Hakeim HK, Asad HN, Maes M. Wnt/β-catenin pathway proteins in end-stage renal disease. Biomark Med 2021;15:1423-34. [PMID: 34554011 DOI: 10.2217/bmm-2021-0177] [Reference Citation Analysis]
18 Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-peralta F. Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. JCM 2022;11:968. [DOI: 10.3390/jcm11040968] [Reference Citation Analysis]
19 Wang M, Zhang R, Wang M, Zhang L, Ding Y, Tang Z, Wang H, Zhang W, Chen Y, Wang J. Genetic Polymorphism of Vitamin D Family Genes CYP2R1, CYP24A1, and CYP27B1 Are Associated With a High Risk of Non-alcoholic Fatty Liver Disease: A Case-Control Study. Front Genet 2021;12:717533. [PMID: 34484304 DOI: 10.3389/fgene.2021.717533] [Reference Citation Analysis]
20 Clough GF, Chipperfield AJ, Thanaj M, Scorletti E, Calder PC, Byrne CD. Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis. Front Physiol 2020;11:551. [PMID: 32581841 DOI: 10.3389/fphys.2020.00551] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology. 2021;73:833-842. [PMID: 32780879 DOI: 10.1002/hep.31518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 35.0] [Reference Citation Analysis]
22 Cojocariu C, Singeap AM, Girleanu I, Chiriac S, Muzica CM, Sfarti CV, Cuciureanu T, Huiban L, Stanciu C, Trifan A. Nonalcoholic Fatty Liver Disease-Related Chronic Kidney Disease. Can J Gastroenterol Hepatol 2020;2020:6630296. [PMID: 33457399 DOI: 10.1155/2020/6630296] [Reference Citation Analysis]
23 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
24 Kwon HC, Song JJ, Park YB, Lee SW. Fibrosis-5 predicts end-stage renal disease in patients with microscopic polyangiitis and granulomatosis with polyangiitis without substantial liver diseases. Clin Exp Med 2021;21:399-406. [PMID: 33611672 DOI: 10.1007/s10238-021-00691-2] [Reference Citation Analysis]
25 Ye L, Hu X, Hu X, Yin S, Chen J, He H, Hong S, Yang B, Singh KK, Feng J, Wang Y, Luo W, Liang G. Curcumin analogue C66 attenuates obesity-induced renal injury by inhibiting chronic inflammation. Biomed Pharmacother 2021;137:111418. [PMID: 33761621 DOI: 10.1016/j.biopha.2021.111418] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
26 Morales E, Porrini E, Martin-Taboada M, Luis-Lima S, Vila-Bedmar R, González de Pablos I, Gómez P, Rodríguez E, Torres L, Lanzón B, Rodríguez AE, Maíz M, Medina-Gómez G, Praga M. Renoprotective role of bariatric surgery in patients with established chronic kidney disease. Clin Kidney J 2021;14:2037-46. [PMID: 34476090 DOI: 10.1093/ckj/sfaa266] [Reference Citation Analysis]
27 Huang TS, Wu IW, Lin CL, Shyu YC, Chen YC, Chien RN. Prognosis of Chronic Kidney Disease in Patients with Non-Alcoholic Fatty Liver Disease: a Northeastern Taiwan Community Medicine Research Cohort. Biomed J 2022:S2319-4170(22)00058-0. [PMID: 35460926 DOI: 10.1016/j.bj.2022.04.003] [Reference Citation Analysis]
28 Cho Y, Chang Y, Ryu S, Jung HS, Kim CW, Oh H, Kim MK, Sohn W, Shin H, Wild SH, Byrne CD. Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. Hepatol Commun 2022. [PMID: 35503803 DOI: 10.1002/hep4.1975] [Reference Citation Analysis]
29 Boike JR, Mazumder NR, Kolli KP, Ge J, German M, Jest N, Morelli G, Spengler E, Said A, Lai JC, Desai AP, Couri T, Paul S, Frenette C, Verna EC, Rahim U, Goel A, Gregory D, Thornburg B, VanWagner LB; Advancing Liver Therapeutic Approaches (ALTA) Study Group. Outcomes After TIPS for Ascites and Variceal Bleeding in a Contemporary Era-An ALTA Group Study. Am J Gastroenterol 2021. [PMID: 34158464 DOI: 10.14309/ajg.0000000000001357] [Reference Citation Analysis]
30 Fontecha-Barriuso M, Martin-Sanchez D, Martinez-Moreno JM, Monsalve M, Ramos AM, Sanchez-Niño MD, Ruiz-Ortega M, Ortiz A, Sanz AB. The Role of PGC-1α and Mitochondrial Biogenesis in Kidney Diseases. Biomolecules 2020;10:E347. [PMID: 32102312 DOI: 10.3390/biom10020347] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
31 Sharma M, Singh V, Sharma R, Koul A, Mccarthy ET, Savin VJ, Joshi T, Srivastava T. Glomerular Biomechanical Stress and Lipid Mediators during Cellular Changes Leading to Chronic Kidney Disease. Biomedicines 2022;10:407. [DOI: 10.3390/biomedicines10020407] [Reference Citation Analysis]
32 Gao F, He Q, Li G, Huang OY, Tang LJ, Wang XD, Targher G, Byrne CD, Luo JW, Zheng MH. A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis. Liver Int 2021. [PMID: 34564946 DOI: 10.1111/liv.15064] [Reference Citation Analysis]
33 Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population. Dig Liver Dis 2021;53:866-72. [PMID: 33685807 DOI: 10.1016/j.dld.2021.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Aubert L, Sandino J, Gutiérrez-Solís E, García-Martín F, Segura J, Porrini E, Morales E. Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus. Nephrol Dial Transplant 2021:gfab176. [PMID: 33983444 DOI: 10.1093/ndt/gfab176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Liu SY, Huang CC, Huang SF, Liao TL, Kuo NR, Yang YY, Li TH, Liu CW, Hou MC, Lin HC. Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats. Cells 2021;10:3044. [PMID: 34831270 DOI: 10.3390/cells10113044] [Reference Citation Analysis]
36 Venniyoor A, Al Farsi AA, Al Bahrani B. The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC). Cureus 2021;13:e17320. [PMID: 34557366 DOI: 10.7759/cureus.17320] [Reference Citation Analysis]
37 Cheng B, Zhou AZ, Ge W, Yao XM, Wang J. Mechanism of Huo-Xue-Qu-Yu Formula in Treating Nonalcoholic Hepatic Steatosis by Regulating Lipid Metabolism and Oxidative Stress in Rats. Evid Based Complement Alternat Med 2021;2021:6026319. [PMID: 34007294 DOI: 10.1155/2021/6026319] [Reference Citation Analysis]
38 Mende C, Einhorn D. Fatty kidney disease: The importance of ectopic fat deposition and the potential value of imaging. J Diabetes 2021. [PMID: 34704674 DOI: 10.1111/1753-0407.13232] [Reference Citation Analysis]
39 Targher G, Mantovani A, Grander C, Foco L, Motta B, Byrne CD, Pramstaller PP, Tilg H. Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. Nutr Metab Cardiovasc Dis 2021;31:3464-73. [PMID: 34627696 DOI: 10.1016/j.numecd.2021.08.037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Sun DQ, Wang TY, Zheng KI, Zhang HY, Wang XD, Targher G, Byrne CD, Chen YP, Yuan WJ, Jin Y, Zheng MH. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2021;31:1822-31. [PMID: 33853719 DOI: 10.1016/j.numecd.2021.02.018] [Reference Citation Analysis]
41 Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. MAFLD and risk of CKD. Metabolism 2021;115:154433. [PMID: 33212070 DOI: 10.1016/j.metabol.2020.154433] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
42 Kanbay M, Bulbul MC, Copur S, Afsar B, Sag AA, Siriopol D, Kuwabara M, Badarau S, Covic A, Ortiz A. Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease. J Nephrol 2021;34:649-59. [PMID: 32440840 DOI: 10.1007/s40620-020-00751-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Tavaglione F, Targher G, Valenti L, Romeo S. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 2020;3:e00179. [PMID: 33102799 DOI: 10.1002/edm2.179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
44 Mantovani A, Beatrice G, Petracca G, Pampagnin F, Sandri D, Targher G. GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis. Exploration of Medicine 2020;1:108-23. [DOI: 10.37349/emed.2020.00008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Lin YC, Wu CC, Ni YH. New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. Front Pediatr 2020;8:603654. [PMID: 33363067 DOI: 10.3389/fped.2020.603654] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
46 Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita K, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? Int J Mol Sci 2020;21:E4939. [PMID: 32668632 DOI: 10.3390/ijms21144939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C. [Chronic kidney injury in patients with liver diseases - Reappraising pathophysiology and treatment options]. Z Gastroenterol 2021;59:560-79. [PMID: 33728618 DOI: 10.1055/a-1402-1502] [Reference Citation Analysis]
48 Chen J, Deng X, Liu Y, Tan Q, Huang G, Che Q, Guo J, Su Z. Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe? Int J Biol Sci 2020;16:2367-78. [PMID: 32760204 DOI: 10.7150/ijbs.47143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
49 Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules 2022;12:105. [DOI: 10.3390/biom12010105] [Reference Citation Analysis]
50 Reinson T, Byrne CD, Patel J, El-Gohary M, Moore M. Transient elastography in patients at risk of liver fibrosis in primary care: a follow-up study over 54 months. BJGP Open 2021;5:BJGPO. [PMID: 34580065 DOI: 10.3399/BJGPO.2021.0145] [Reference Citation Analysis]
51 Guo Y, Huang H, Chen Y, Shen C, Xu C. Association between circulating cystatin C and hyperuricemia: a cross-sectional study. Clin Rheumatol 2022. [PMID: 35355151 DOI: 10.1007/s10067-022-06139-6] [Reference Citation Analysis]
52 Li M, Zhao Z, Qin G, Chen L, Lu J, Huo Y, Chen L, Zeng T, Xu M, Chen Y, Wang T, Wang S, Xu Y, Shi L, Tang X, Su Q, Yu X, Yan L, Wan Q, Chen G, Gao Z, Wang G, Shen F, Luo Z, Zhang Y, Liu C, Wang Y, Hu R, Ye Z, Wu S, Deng H, Yang T, Li Q, Qin Y, Mu Y, Zhao J, Ning G, Bi Y, Xu Y, Wang W. Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes. Metabolism 2021;124:154874. [PMID: 34517014 DOI: 10.1016/j.metabol.2021.154874] [Reference Citation Analysis]
53 Deng Y, Zhao Q, Gong R. Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018. Diabetes Metab Syndr Obes 2021;14:1751-61. [PMID: 33911888 DOI: 10.2147/DMSO.S292926] [Reference Citation Analysis]
54 Zuo G, Xuan L, Xin Z, Xu Y, Lu J, Chen Y, Dai M, Zhang D, Wang W, Li M, Bi Y, Ning G, Xu M. New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease. J Clin Endocrinol Metab 2021:dgab425. [PMID: 34125886 DOI: 10.1210/clinem/dgab425] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
56 Sarkar S, Chen S, Spencer B, Situ X, Afkarian M, Matsukuma K, Corwin MT, Wang G. Non-Alcoholic Steatohepatitis Severity Associates with FGF21 Level and Kidney Glucose Uptake. Metab Syndr Relat Disord 2021;19:491-7. [PMID: 34448598 DOI: 10.1089/met.2021.0055] [Reference Citation Analysis]
57 Cai X, Sun L, Liu X, Zhu H, Zhang Y, Zheng S, Huang Y. Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease. Ther Adv Chronic Dis 2021;12:20406223211024361. [PMID: 34249302 DOI: 10.1177/20406223211024361] [Reference Citation Analysis]
58 Bilson J, Scorletti E, Bindels LB, Afolabi PR, Targher G, Calder PC, Sethi JK, Byrne CD. Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. Nutr Diabetes 2021;11:32. [PMID: 34663793 DOI: 10.1038/s41387-021-00170-3] [Reference Citation Analysis]
59 Truong E, Noureddin M. The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.008] [Reference Citation Analysis]
60 Cazanave SC, Warren AD, Pacula M, Touti F, Zagorska A, Gural N, Huang EK, Sherman S, Cheema M, Ibarra S, Bates J, Billin AN, Liles JT, Budas GR, Breckenridge DG, Tiniakos D, Ratziu V, Daly AK, Govaere O, Anstee QM, Gelrud L, Luther J, Chung RT, Corey KE, Winckler W, Bhatia S, Kwong GA. Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. Sci Transl Med 2021;13:eabe8939. [PMID: 34669440 DOI: 10.1126/scitranslmed.abe8939] [Reference Citation Analysis]
61 Zhong L, Wu C, Li Y, Zeng Q, Lai L, Chen S, Tang S. Nonalcoholic fatty liver disease and health outcomes: An umbrella review of systematic reviews and meta-analyses. Therapeutic Advances in Chronic Disease 2022;13:204062232210835. [DOI: 10.1177/20406223221083508] [Reference Citation Analysis]
62 Altshuler PJ, Shah AP, Frank AM, Glorioso J, Dang H, Shaheen O, Patel K, Ramirez CB, Maley WR, Bodzin AS. Simultaneous liver kidney allocation policy and the Safety Net: an early examination of utilization and outcomes in the United States. Transpl Int 2021;34:1052-64. [PMID: 33884677 DOI: 10.1111/tri.13891] [Reference Citation Analysis]
63 Abbate M, Mascaró CM, Montemayor S, Barbería-Latasa M, Casares M, Gómez C, Angullo-Martinez E, Tejada S, Abete I, Zulet MA, Sureda A, Martínez JA, Tur JA. Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients. Nutrients 2021;13:629. [PMID: 33672073 DOI: 10.3390/nu13020629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Johnston MP, Patel J, Byrne CD. Update on cardiovascular risk in nonalcoholic fatty liver disease. Curr Opin Cardiol 2021;36:478-86. [PMID: 34059612 DOI: 10.1097/HCO.0000000000000861] [Reference Citation Analysis]
65 Minjares RO, Martin P, Carrion AF. Chronic Kidney Disease After Liver Transplantation. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.006] [Reference Citation Analysis]
66 Shaji N, Singhai A, Sarawagi R, Pakhare AP, Mishra VN, Joshi R. Assessment of Liver Fibrosis Using Non-invasive Screening Tools in Individuals With Diabetes Mellitus and Metabolic Syndrome. Cureus. [DOI: 10.7759/cureus.22682] [Reference Citation Analysis]
67 Gao F, Zheng KI, Chen SD, Lee DH, Wu XX, Wang XD, Targher G, Byrne CD, Chen YP, Kim W, Zheng MH. Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. Clin Transl Gastroenterol 2021;12:e00321. [PMID: 33704100 DOI: 10.14309/ctg.0000000000000321] [Reference Citation Analysis]
68 Pellicori P, Vaduganathan M, Ferreira JP, Zannad F, Sanyal AJ. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. Diabetes Metab 2021;:101281. [PMID: 34543735 DOI: 10.1016/j.diabet.2021.101281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Di Sessa A, Umano GR, Cirillo G, Passaro AP, Verde V, Cozzolino D, Guarino S, Marzuillo P, Miraglia del Giudice E. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant. World J Gastroenterol 2020; 26(36): 5474-5483 [PMID: 33024398 DOI: 10.3748/wjg.v26.i36.5474] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
70 Cao Y, Deng Y, Wang J, Zhao H, Zhang J, Xie W. The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. Ther Adv Chronic Dis 2021;12:20406223211048649. [PMID: 34777740 DOI: 10.1177/20406223211048649] [Reference Citation Analysis]
71 Yang M, Geng CA, Liu X, Guan M. Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines 2021;9:1405. [PMID: 34680522 DOI: 10.3390/biomedicines9101405] [Reference Citation Analysis]
72 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
73 Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? J Clin Med 2021;10:2040. [PMID: 34068699 DOI: 10.3390/jcm10092040] [Reference Citation Analysis]
74 Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Reference Citation Analysis]
75 Lu FB, Zheng KI, Rios RS, Targher G, Byrne CD, Zheng MH. Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2020;35:2041-50. [PMID: 32573017 DOI: 10.1111/jgh.15156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
76 Adrian T, Sørensen IMH, Knop FK, Bro S, Ballegaard ELF, Nordestgaard BG, Fuchs A, Kofoed KF, Kühl JT, Sigvardsen PE, Hornum M, Feldt-Rasmussen B. Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a case-control study. Nephrol Dial Transplant 2021:gfab266. [PMID: 34505899 DOI: 10.1093/ndt/gfab266] [Reference Citation Analysis]
77 Di Sessa A, Guarino S, Passaro AP, Liguori L, Umano GR, Cirillo G, Miraglia Del Giudice E, Marzuillo P. NAFLD and renal function in children: is there a genetic link?Expert Rev Gastroenterol Hepatol. 2021;1-10. [PMID: 33851883 DOI: 10.1080/17474124.2021.1906649] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Kaps L, Labenz C, Galle PR, Weinmann-Menke J, Kostev K, Schattenberg JM. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterol J 2020;8:942-8. [PMID: 32698692 DOI: 10.1177/2050640620944098] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
79 Kotoku K, Michishita R, Matsuda T, Kawakami S, Morito N, Uehara Y, Higaki Y. The Association between Decreased Kidney Function and FIB-4 Index Value, as Indirect Liver Fibrosis Indicator, in Middle-Aged and Older Subjects. Int J Environ Res Public Health 2021;18:6980. [PMID: 34209974 DOI: 10.3390/ijerph18136980] [Reference Citation Analysis]
80 Wu H, He X, Li Q, Zheng Y, Rayamajhi S, Thapa A, Meng G, Zhang Q, Liu L, Wu H, Gu Y, Zhang S, Zhang T, Wang X, Zhang J, Cao Z, Dong J, Zheng X, Zhang X, Dong X, Sun S, Wang X, Zhou M, Jia Q, Song K, Chang H, Niu K. Relationship between the consumption of wholegrain and nonalcoholic fatty liver disease: The TCLSIH cohort study. Clinical Nutrition 2022. [DOI: 10.1016/j.clnu.2022.05.009] [Reference Citation Analysis]
81 Mikolasevic I, Rahelic D, Turk-Wensween T, Ruzic A, Domislovic V, Hauser G, Matic T, Radic-Kristo D, Krznaric Z, Radic M, Filipec Kanizaj T, Martinovic M, Jerkic H, Medjimurec M, Targher G. Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study. Diabetes Res Clin Pract 2021;177:108884. [PMID: 34082054 DOI: 10.1016/j.diabres.2021.108884] [Reference Citation Analysis]
82 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2020;. [PMID: 33303564 DOI: 10.1136/gutjnl-2020-323082] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
83 Park S, Lee S, Kim Y, Cho S, Kim K, Chul Kim Y, Han SS, Lee H, Lee JP, Joo KW, Lim CS, Kim YS, Kim DK. Causal effects from non-alcoholic fatty liver disease on kidney function: A Mendelian randomization study. Liver Int 2021. [PMID: 34843158 DOI: 10.1111/liv.15118] [Reference Citation Analysis]
84 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2021;69:1691-705. [DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 26.5] [Reference Citation Analysis]
85 Alipour MR, Jeddi S, Karimi-Sales E. trans-Chalcone inhibits high-fat diet-induced disturbances in FXR/SREBP-1c/FAS and FXR/Smad-3 pathways in the kidney of rats. J Food Biochem 2020;44:e13476. [PMID: 32944984 DOI: 10.1111/jfbc.13476] [Reference Citation Analysis]